Sumitomo Dainippon Pharma (SDP) has merged two of its US-based wholly owned subsidiaries, Tolero Pharmaceuticals and Boston Biomedical, to form Sumitomo Dainippon Pharma Oncology, the company said in a statement Wednesday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
